Literature DB >> 29514324

Tobacco Smoking and Brain Endogenous Opioid Release: More Than Nicotine Alone.

Edward F Domino1, Mika Hirasawa-Fujita1.   

Abstract

INTRODUCTION: The effects of smoking denicotinized (denic) and average nicotine (avnic) tobacco cigarettes were studied on brain mu opioid receptor binding by positron emission tomography with 11C carfentanil. The results indicated the importance of physiological and psychological effects induced by denic smoking.
METHODS: Regional mu opioid binding potential (nondisplaceable binding potential, BPND) was measured in 20 adult male overnight abstinent chronic tobacco smokers. The denic sessions were conducted about 8:00 am followed by avnic sessions about 2 hours later. Venous plasma nicotine levels and scores of craving to smoke were assessed before and after each smoking session. Fagerstrom scores of nicotine dependence were determined. Pearson's and Spearman's correlation tests were used to examine associations between BPND and other smoking parameters.
RESULTS: Surprisingly, the very low plasma nicotine peak levels after denic smoking (mean ± SD: 3.3 ± 1.8 ng/mL) were significantly correlated with BPND after denic and avnic smoking. Equally surprising no association was found between nicotine levels after avnic smoking and BPND. Delta craving scores and Fagerstrom scores were correlated with both BPND after denic and avnic in several brain regions.
CONCLUSIONS: Very small amounts of nicotine, psychological and behavioral effects of denic smoking appear to have important actions on the endogenous mu opioid system. IMPLICATIONS: Associations between very low venous plasma nicotine levels after denic smoking and regional brain mu opioid receptor availability are a surprising "placebo" effect. Delta craving and Fagerstrom scores were correlated with BPND in several brain regions including amygdala, hippocampus, insula, nucleus accumbens, putamen, and ventral striatum. This study is limited by modest Power (mean 1 - β = 0.6) for all correlation analyses.
© The Author(s) 2018. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 29514324      PMCID: PMC6528147          DOI: 10.1093/ntr/nty039

Source DB:  PubMed          Journal:  Nicotine Tob Res        ISSN: 1462-2203            Impact factor:   4.244


  27 in total

Review 1.  Nicotine and hippocampus-dependent learning: implications for addiction.

Authors:  Thomas J Gould
Journal:  Mol Neurobiol       Date:  2006-10       Impact factor: 5.590

2.  Reinforcing effects of nicotine and non-nicotine components of cigarette smoke.

Authors:  Jed E Rose; Al Salley; Frederique M Behm; James E Bates; Eric C Westman
Journal:  Psychopharmacology (Berl)       Date:  2010-04-01       Impact factor: 4.530

3.  Hippocampal and Insular Response to Smoking-Related Environments: Neuroimaging Evidence for Drug-Context Effects in Nicotine Dependence.

Authors:  F Joseph McClernon; Cynthia A Conklin; Rachel V Kozink; R Alison Adcock; Maggie M Sweitzer; Merideth A Addicott; Ying-hui Chou; Nan-kuei Chen; Matthew B Hallyburton; Anthony M DeVito
Journal:  Neuropsychopharmacology       Date:  2015-07-16       Impact factor: 7.853

4.  Effects of the Mu opioid receptor polymorphism (OPRM1 A118G) on pain regulation, placebo effects and associated personality trait measures.

Authors:  Marta Peciña; Tiffany Love; Christian S Stohler; David Goldman; Jon-Kar Zubieta
Journal:  Neuropsychopharmacology       Date:  2014-10-13       Impact factor: 7.853

5.  Human Mu Opioid Receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers.

Authors:  Riju Ray; Kosha Ruparel; Andrew Newberg; E Paul Wileyto; James W Loughead; Chaitanya Divgi; Julie A Blendy; Jean Logan; Jon-Kar Zubieta; Caryn Lerman
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-16       Impact factor: 11.205

6.  Smoking without nicotine delivery decreases withdrawal in 12-hour abstinent smokers.

Authors:  M F Butschky; D Bailey; J E Henningfield; W B Pickworth
Journal:  Pharmacol Biochem Behav       Date:  1995-01       Impact factor: 3.533

Review 7.  Nicotine and smokeless tobacco.

Authors:  N L Benowitz
Journal:  CA Cancer J Clin       Date:  1988 Jul-Aug       Impact factor: 508.702

8.  Morphine-nicotine interaction in conditioned place preference in mice after chronic nicotine exposure.

Authors:  Tanja Vihavainen; Marjo Piltonen; Raimo K Tuominen; Esa R Korpi; Liisa Ahtee
Journal:  Eur J Pharmacol       Date:  2008-04-01       Impact factor: 4.432

9.  Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses.

Authors:  David J Scott; Christian S Stohler; Christine M Egnatuk; Heng Wang; Robert A Koeppe; Jon-Kar Zubieta
Journal:  Arch Gen Psychiatry       Date:  2008-02

10.  Regional brain [(11)C]carfentanil binding following tobacco smoking.

Authors:  Edward F Domino; Mika Hirasawa-Fujita; Lisong Ni; Sally K Guthrie; Jon Kar Zubieta
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2015-01-15       Impact factor: 5.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.